These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32105524)

  • 1. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
    Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
    Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
    [No Abstract]   [Full Text] [Related]  

  • 2. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
    He J; Liu Y; Zhang L; Zhang H
    Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer.
    Zhang QF; Li YK; Chen CY; Zhang XD; Cao L; Quan FF; Zeng X; Wang J; Liu J
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
    Cho SY; Kim K; Park MS; Jang MY; Choi YH; Han S; Shin HM; Chung C; Han HY; Yang JB; Ko YB; Yoo HJ
    Oncol Rep; 2017 May; 37(5):2620-2632. PubMed ID: 28339095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc Finger Protein 24 is a Prognostic Factor in Ovarian Serous Carcinoma.
    Chen J; Guo J; Yuan Y; Wang Y
    Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):136-144. PubMed ID: 34608874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer.
    Zong S; Xu PP; Xu YH; Guo Y
    J Ovarian Res; 2022 Aug; 15(1):90. PubMed ID: 35915456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
    Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
    Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
    Huang C; Cui H; Lang X; Zhao F
    J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
    Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
    J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.
    Li H; Xiao N; Li Z; Wang Q
    Tohoku J Exp Med; 2017 Feb; 241(2):165-173. PubMed ID: 28202851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
    Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
    BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
    PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Oh CK; Park JJ; Ha M; Heo HJ; Kang J; Kwon EJ; Kang JW; Kim Y; Kang JM; Yoon SZ; Ko Y; Ko DS; Kim YH
    Anticancer Res; 2020 Oct; 40(10):5601-5609. PubMed ID: 32988884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
    Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
    Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Schimp V; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2005 Jul; 24(3):228-34. PubMed ID: 15968197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.